Herombopag Added to Cyclosporine in Non Severe Aplastic Anemia

Phase 2 Completed 54 enrolled Institute of Hematology & Blood Diseases Hospital, China Jiangsu Hengrui Pharmaceutical Co., Ltd. · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a prospective, multicenter, single-arm, phase 2 trial. The aim of this study is to evaluate the efficacy and safety of herombopag combined with cyclosporine for patients with non severe aplastic anemia (NSAA).

Timeline

Start: 2022-12-01
Primary completion: 2025-01-20
Completion: 2025-01-28

Publications

Zhang L, Li R, Liang Q, Li W, Pan H, Gao Z, Fang L, Zhao J, Yu X, Kuang Z, Nie N, Li J, Huang J, Zhao X, Ge M, Zheng Y, Li J, Zhang H, Shi J. Hetrombopag Added to Cyclosporine as the First-Line Treatment for Patients With Non-Severe Aplastic Anemia: A Phase 2 Multicenter Trial. Am J Hematol. 2026 Mar;101(3):467-476. doi: 10.1002/ajh.70183. Epub 2026 Jan 5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	RAFUTROMBOPAG	Other / unclassified	—	Oral
Background	Cyclosporine	Peptide	—	—

Herombopag Added to Cyclosporine in Non Severe Aplastic Anemia

Summary

Timeline

Publications

Drugs

Indications